Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study.
<h4>Background</h4>People infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) experience a wide range of clinical manifestations, from asymptomatic and mild illness to severe illness and death, influenced by age and a variety of comorbidities. Neutralizing antibodi...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-12-01
|
| Series: | PLoS Medicine |
| Online Access: | https://doi.org/10.1371/journal.pmed.1003868 |
| _version_ | 1811283543999905792 |
|---|---|
| author | Shelly Karuna Shuying Sue Li Shannon Grant Stephen R Walsh Ian Frank Martin Casapia Meg Trahey Ollivier Hyrien Leigh Fisher Maurine D Miner April K Randhawa Laura Polakowski James G Kublin Lawrence Corey David Montefiori HVTN 405/HPTN 1901 Study Team |
| author_facet | Shelly Karuna Shuying Sue Li Shannon Grant Stephen R Walsh Ian Frank Martin Casapia Meg Trahey Ollivier Hyrien Leigh Fisher Maurine D Miner April K Randhawa Laura Polakowski James G Kublin Lawrence Corey David Montefiori HVTN 405/HPTN 1901 Study Team |
| author_sort | Shelly Karuna |
| collection | DOAJ |
| description | <h4>Background</h4>People infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) experience a wide range of clinical manifestations, from asymptomatic and mild illness to severe illness and death, influenced by age and a variety of comorbidities. Neutralizing antibodies (nAbs) are thought to be a primary immune defense against the virus. Large, diverse, well-characterized cohorts of convalescent individuals provide standardized values to benchmark nAb responses to past SARS-CoV-2 infection and define potentially protective levels of immunity.<h4>Methods and findings</h4>This analysis comprises an observational cohort of 329 HIV-seronegative adults in the United States (n = 167) and Peru (n = 162) convalescing from SARS-CoV-2 infection from May through October 2020. The mean age was 48 years (range 18 to 86), 54% of the cohort overall was Hispanic, and 34% identified as White. nAb titers were measured in serum by SARS-CoV-2.D614G Spike-pseudotyped virus infection of 293T/ACE2 cells. Multiple linear regression was applied to define associations between nAb titers and demographic variables, disease severity and time from infection or disease onset, and comorbidities within and across US and Peruvian cohorts over time. nAb titers peaked 28 to 42 days post-diagnosis and were higher in participants with a history of severe Coronavirus Disease 2019 (COVID-19) (p < 0.001). Diabetes, age >55 years, male sex assigned at birth, and, in some cases, body mass index were also independently associated with higher nAb titers, whereas hypertension was independently associated with lower nAb titers. nAb titers did not differ by race, underlying pulmonary disease or smoking. Two months post-enrollment, nAb ID50 (ID80) titers declined 3.5 (2.8)-fold overall. Study limitations in this observational, convalescent cohort include survivorship bias and missing early viral loads and acute immune responses to correlate with the convalescent responses we observed.<h4>Conclusions</h4>In summary, in our cohort, nAb titers after SARS-CoV-2 infection peaked approximately 1 month post-diagnosis and varied by age, sex assigned at birth, disease severity, and underlying comorbidities. Our data show great heterogeneity in nAb responses among people with recent COVID-19, highlighting the challenges of interpreting natural history studies and gauging responses to vaccines and therapeutics among people with recent infection. Our observations illuminate potential correlations of demographic and clinical characteristics with nAb responses, a key element for protection from COVID-19, thus informing development and implementation of preventative and therapeutic strategies globally.<h4>Trial registration</h4>ClinicalTrials.gov NCT04403880. |
| first_indexed | 2024-04-13T02:14:37Z |
| format | Article |
| id | doaj.art-264da4fa22534ccfbdbd68057f09e889 |
| institution | Directory Open Access Journal |
| issn | 1549-1277 1549-1676 |
| language | English |
| last_indexed | 2024-04-13T02:14:37Z |
| publishDate | 2021-12-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj.art-264da4fa22534ccfbdbd68057f09e8892022-12-22T03:07:12ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762021-12-011812e100386810.1371/journal.pmed.1003868Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study.Shelly KarunaShuying Sue LiShannon GrantStephen R WalshIan FrankMartin CasapiaMeg TraheyOllivier HyrienLeigh FisherMaurine D MinerApril K RandhawaLaura PolakowskiJames G KublinLawrence CoreyDavid MontefioriHVTN 405/HPTN 1901 Study Team<h4>Background</h4>People infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) experience a wide range of clinical manifestations, from asymptomatic and mild illness to severe illness and death, influenced by age and a variety of comorbidities. Neutralizing antibodies (nAbs) are thought to be a primary immune defense against the virus. Large, diverse, well-characterized cohorts of convalescent individuals provide standardized values to benchmark nAb responses to past SARS-CoV-2 infection and define potentially protective levels of immunity.<h4>Methods and findings</h4>This analysis comprises an observational cohort of 329 HIV-seronegative adults in the United States (n = 167) and Peru (n = 162) convalescing from SARS-CoV-2 infection from May through October 2020. The mean age was 48 years (range 18 to 86), 54% of the cohort overall was Hispanic, and 34% identified as White. nAb titers were measured in serum by SARS-CoV-2.D614G Spike-pseudotyped virus infection of 293T/ACE2 cells. Multiple linear regression was applied to define associations between nAb titers and demographic variables, disease severity and time from infection or disease onset, and comorbidities within and across US and Peruvian cohorts over time. nAb titers peaked 28 to 42 days post-diagnosis and were higher in participants with a history of severe Coronavirus Disease 2019 (COVID-19) (p < 0.001). Diabetes, age >55 years, male sex assigned at birth, and, in some cases, body mass index were also independently associated with higher nAb titers, whereas hypertension was independently associated with lower nAb titers. nAb titers did not differ by race, underlying pulmonary disease or smoking. Two months post-enrollment, nAb ID50 (ID80) titers declined 3.5 (2.8)-fold overall. Study limitations in this observational, convalescent cohort include survivorship bias and missing early viral loads and acute immune responses to correlate with the convalescent responses we observed.<h4>Conclusions</h4>In summary, in our cohort, nAb titers after SARS-CoV-2 infection peaked approximately 1 month post-diagnosis and varied by age, sex assigned at birth, disease severity, and underlying comorbidities. Our data show great heterogeneity in nAb responses among people with recent COVID-19, highlighting the challenges of interpreting natural history studies and gauging responses to vaccines and therapeutics among people with recent infection. Our observations illuminate potential correlations of demographic and clinical characteristics with nAb responses, a key element for protection from COVID-19, thus informing development and implementation of preventative and therapeutic strategies globally.<h4>Trial registration</h4>ClinicalTrials.gov NCT04403880.https://doi.org/10.1371/journal.pmed.1003868 |
| spellingShingle | Shelly Karuna Shuying Sue Li Shannon Grant Stephen R Walsh Ian Frank Martin Casapia Meg Trahey Ollivier Hyrien Leigh Fisher Maurine D Miner April K Randhawa Laura Polakowski James G Kublin Lawrence Corey David Montefiori HVTN 405/HPTN 1901 Study Team Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. PLoS Medicine |
| title | Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. |
| title_full | Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. |
| title_fullStr | Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. |
| title_full_unstemmed | Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. |
| title_short | Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. |
| title_sort | neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from sars cov 2 infection in the united states and peru a cohort study |
| url | https://doi.org/10.1371/journal.pmed.1003868 |
| work_keys_str_mv | AT shellykaruna neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT shuyingsueli neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT shannongrant neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT stephenrwalsh neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT ianfrank neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT martincasapia neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT megtrahey neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT ollivierhyrien neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT leighfisher neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT maurinedminer neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT aprilkrandhawa neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT laurapolakowski neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT jamesgkublin neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT lawrencecorey neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT davidmontefiori neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy AT hvtn405hptn1901studyteam neutralizingantibodyresponsesovertimeindemographicallyandclinicallydiverseindividualsrecoveredfromsarscov2infectionintheunitedstatesandperuacohortstudy |